A Phase 1, Randomised, Double-blind, Placebo-controlled, Single and Multiple Ascending Dose Study to Assess the Safety, Tolerability and Pharmacokinetics of Imeglimin in Healthy Japanese Subjects
Phase of Trial: Phase I
Latest Information Update: 22 May 2017
At a glance
- Drugs Imeglimin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Poxel
- 22 May 2017 According to a Poxel media release, results from this trial were presented at the 9th Scientific Meeting of the Asian Association for the Study of Diabetes (AASD).
- 20 Apr 2017 According to a Poxel media release, results from this trial will be presented at the Asian Association for the Study of Diabetes, which is being held in conjunction with the 60th Annual Meeting of The Japan Diabetes Society.
- 27 May 2015 Results published in the Poxel Media Release.